Adial Pharmaceuticals Inc (ADIL)

Stock Price Forecast

March 22, 2023

Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict

Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Adial Pharmaceuticals Inc chart...

About the Company

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) and is currently being investigated in the Company's landmark ONWARD™ pivotal Phase 3 clinical trial for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). AD04 is also believed to have the potential to treat other addictive disorders such as Opioid Use Disorder, gambling, and obesity.





Total Revenue




Market Capitalization


Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ADIL News

Adial Pharmaceuticals Engages The Keswick Group to Advance Partnering Activities for the Clinical Development of AD04 for Alcohol Use Disorder

1d ago, source:

The Keswick Group is led by experienced pharmaceutical business development executive, Tony GoodmanCHARLOTTESVILLE, Va., ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL): Is Breakeven Near?

22d ago, source: Yahoo Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Adial Pharmaceuticals, Inc.'s (NASDAQ:ADIL) future prospects. Adial Pharmaceuticals, Inc., a clinical ...

Why Adial Pharmaceuticals Shares Are Trading Higher By Around 65%; Here Are 20 Stocks Moving Premarket

on MSN ago, source:

Gainers Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) rose 64.6% to $0.6912 in pre-market trading after the company provided an update on its regulatory strategy for AD04. Adial will pursue paths towards ...

Adial Pharmaceuticals Inc (ADIL)

27d ago, source: Investing

Adial Pharmaceuticals (NASDAQ:ADIL), Inc. (ADIL; ADILW) today provided an update on its regulatory strategy for AD04, the Company’s lead compound for the treatment of Alcohol Use Disorder (AUD ...

Adial Pharmaceuticals Provides Update on Regulatory Strategy for AD04 for Treatment of Alcohol Use Disorder

16d ago, source:

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) ("Adial" or the "Company") a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction ...

Maxim Group Sticks to Its Hold Rating for Adial Pharmaceuticals (ADIL)

13d ago, source: Business Insider

Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 ...

Adial Pharmaceuticals Schedules Business Update Conference Call

19d ago, source: Yahoo! Sports

CHARLOTTESVILLE, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage ...

VLON Vallon Pharmaceuticals, Inc.

3d ago, source: Seeking Alpha

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse ...

What Makes Theseus Pharmaceuticals, Inc. (THRX) a New Buy Stock

8d ago, source: Nasdaq

Theseus Pharmaceuticals, Inc. (THRX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings ...

Latest Neutral (free) Forecasts


Loading the latest forecasts...

My Portfolio

Loading your portfolio...